GenVec will receive up to $2.3 million for the 4th year to support the generation of HIV vaccine candidates with GenVec’s alternate adenovirus serotype technology. The National Institute of Allergy and Infectious Disease (NIAID) has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 million for the production of HIV vaccines.
If you would like to make a comment, please fill out the form below.
Featured Reports
